1 |
Sokolowska-Wojdylo M, Olek-Hrab K, Ruckemann-Dziurdzinska K. Primary cutaneous lymphomas: diagnosis and treatment. Postepy Dermatol Alergol. 2015;32:368-383.
|
2 |
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703-1714.
DOI
|
3 |
Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Myeloma Leuk. 2012;12:291-296.
DOI
|
4 |
Lee HS, Suh KS, Lee DY, Cho KH, Oh SH, Kim SC, et al. Cutaneous lymphoma in Korea: A nationwide retrospective study. Acta Derm Venereol. 2016;96:535-539.
DOI
|
5 |
Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118:4024-4035.
DOI
|
6 |
Kempf W, Sander CA. Classification of cutaneous lymphomas: An update. Histopathology. 2010;56:57-70.
DOI
|
7 |
Sidiropoulos KG, Martinez-Escala ME, Yelamos O, Guitart J, Sidiropoulos M. Primary cutaneous T-cell lymphomas: A review. J Clin Pathol. 2015;68:1003-1010.
DOI
|
8 |
Fujita H, Nagatani T, Miyazawa M, Wada H, Koiwa K, Komatsu H, et al. Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate. Eur J Dermatol. 2008;18:360-361.
DOI
|